Compare FVRR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | ABCL |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.5M | 3.5B |
| IPO Year | 2019 | 2020 |
| Metric | FVRR | ABCL |
|---|---|---|
| Price | $8.76 | $12.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $18.43 | $8.40 |
| AVG Volume (30 Days) | 434.8K | ★ 4.6M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | $21.85 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.61 | $2.75 |
| 52 Week High | $28.00 | $12.58 |
| Indicator | FVRR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 58.33 |
| Support Level | $8.73 | $10.44 |
| Resistance Level | $11.43 | $12.58 |
| Average True Range (ATR) | 0.28 | 0.61 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 25.88 | 46.24 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.